Exhibitors

AA Pharma is committed to consistently meeting Canadian regulatory, quality, and compliance requirements. Our strict adherence ensures we achieve the highest level of quality and consistency in our legacy pharmaceuticals and services so that we can continue to deliver the very best for Canadian patients.

Fetzima is the only SNRI that offers a 2-fold greater selectivity for norepinephrine versus serotonin reuptake inhibition.  Fetzima is a unique SNRI that significantly improved patient motivation, energy and functioning.

Viibryd is a unique SSRI that offers efficacy in MDD with minimal effect on sexual function and weight.  Viibryd is both a selective serotonin reuptake inhibitor and a partial agonist of the 5HT1A receptors.

CLOZARIL® along with the CLOZARIL® Support and Assistance Network (CSAN®) are uniquely effective for a patient population living with treatment-resistant schizophrenia, and has been striving to optimize outcomes since 1991.

We know the brain.

Lundbeck is uncompromisingly committed to the research, development and delivery of targeted therapies for people living with significant psychiatric and neurological disorders. We believe life is too beautiful to be interrupted by brain disorders. So, we pursue imaginative solutions, driven by passionate people committed to do the right thing for our patients, our company and our communities. For Lundbeck, making a meaningful difference for those with lived experience is more than an aspiration: it is a commitment that shapes everything we do. Our advocacy is at the core of who we are and motivates every individual at Lundbeck. Our ongoing engagement with patient communities is not what you might expect from a pharmaceutical company - we work with organizations to help empower people. We believe in challenging the status quo, because Canadians living with brain disorders deserve better.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.ca. We routinely post information that may be important to investors on our website at investor.mylan.com.

The Physician and Family Support Program (PFSP)- a voluntary program that provides confidential support and help with personal health issues. Part of the AMA’s physician benefits program, PFSP enhances the quality of patient care and public safety by supporting the health and well-being of the medical profession that cares for all Albertans.

Shire is strongly driven by a desire to enable Canadians lead better lives and to contribute positively to the health of the communities where we live and operate. As a leader in ADHD education and treatment, Shire’s first obligation is to people who have been appropriately diagnosed with ADHD by a healthcare professional. ADHD is a neurobiological disorder that requires professional management in order for patients to reach their full potential.